An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
NCT ID: NCT01863693
Last Updated: 2018-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2013-05-10
2018-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Line Ovarian Cancer Treatment - Cohort Study
NCT01832415
An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer
NCT02151370
Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer
NCT01982500
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
NCT00937560
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01932125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer not previously treated with chemotherapy
* Initiating Avastin in combination with chemotherapy
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal United Hospital; Oncology Department
Bath, , United Kingdom
City Hospital
Birmingham, , United Kingdom
Bradford Royal Infirmary; Oncology Department
Bradford, , United Kingdom
Bristol Haematology and Oncology Centre
Bristol, , United Kingdom
Queen's Hospital; Oncology Department
Burton-on-Trent, , United Kingdom
Essex County Hospital
Colchester, , United Kingdom
Eastborne District General Hospital
Eastbourne, , United Kingdom
Wonford Hospital; Oncology Department
Exeter, , United Kingdom
Royal Surrey County Hospital
Guildford, , United Kingdom
Ipswich Hospital
Ipswich, , United Kingdom
Airedale General Hospital; Research Office Ward 12
Keighley, , United Kingdom
St James University Hospital
Leeds, , United Kingdom
Royal Marsden Hospital - London
London, , United Kingdom
Maidstone Hospital; Kent Oncology Centre
Maidstone, , United Kingdom
Christie Hospital Nhs Trust; Medical Oncology
Manchester, , United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Metropolitan Borough of Wirral, , United Kingdom
The James Cook University Hospital
Middlesbrough, , United Kingdom
Mount Vernon Hospital
Middlesex, , United Kingdom
St Mary's Hospital
Newport, , United Kingdom
City Campus; Academic Unit of Oncology
Nottingham, , United Kingdom
Queen Alexandra Hospital; Portsmouth Haematology & Oncology Centre, Level B
Portsmouth, , United Kingdom
Weston Park Hospital; Cancer Clinical Trials Centre
Sheffield, , United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
City General Hospital
Stoke-on-Trent, , United Kingdom
The Royal Marsden Hospital
Sutton, , United Kingdom
Singleton Hospital; Oncology
Swansea, , United Kingdom
Torbay Hospital; Oncology Department
Torquay, , United Kingdom
Royal Cornwall Hospital
Truro, , United Kingdom
New Cross Hospital; Deansley Centre
Wolverhampton, , United Kingdom
The York Hospital
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC, Hasan J, Jones R, Ograbek A, Perren TJ. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28570
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.